QQ客服 官方微博 反馈留言

	Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study
	Zhang, Di; Zhang, Chufeng; Huang, Jiaqi; Guan, Yan; Guo, Qisen
刊名	THORACIC CANCER
	2018
卷号	9期号:12页码:1754-1762
关键词	Angiogenesis inhibitor apatinib advanced non-small-cell lung cancer
DOI	10.1111/1759-7714.12898
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4571125
专题	山东大学
作者单位	1.Shandong Univ, Shandong Canc Hosp, Dept Oncol, Jinan, Shandong, Peoples R China. 2.[Zhang, Di 3.Zhang, Chufeng 4.Huang, Jiaqi
推荐引用方式 GB/T 7714	Zhang, Di,Zhang, Chufeng,Huang, Jiaqi,et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study[J]. THORACIC CANCER,2018,9(12):1754-1762.
APA	Zhang, Di,Zhang, Chufeng,Huang, Jiaqi,Guan, Yan,&Guo, Qisen.(2018).Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.THORACIC CANCER,9(12),1754-1762.
MLA	Zhang, Di,et al."Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study".THORACIC CANCER 9.12(2018):1754-1762.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。